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  The aim of this study was to examine the efficacy of in ovo 
prime-boost vaccination against infectious bursal disease 
virus (IBDV) using a DNA vaccine to prime in ovo followed 
by a killed-vaccine boost post hatching. In addition, the adjuvant 
effects of plasmid-encoded chicken interleukin-2 and chicken 
interferon-γ were tested in conjunction with the vaccine. A 
plasmid DNA vaccine (pcDNA-VP243) encoding the VP2, 
VP4, and VP3 proteins of the very virulent IBDV (vvIBDV) 
SH/92 strain was injected into the amniotic sac alone or in 
combination with a plasmid encoding chicken IL-2 (ChIL-2) 
or chicken IFN-γ (ChIFN-γ) at embryonation day 18, followed 
by an intramuscular injection of a commercial killed IBD 
vaccine at 1 week of age. The chickens were orally challenged 
with the vvIBDV SH/92 strain at 3 weeks of age and observed 
for 10 days. In ovo DNA immunization followed by a killed- 
vaccine boost provided significantly better immunity than 
the other options. No mortality was observed in this group 
after a challenge with the vvIBDV. The prime-boost strategy 
was  moderately  effective  against  bursal  damage,  which 
was measured by the bursa weight/body weight ratio, the 
presence of IBDV RNA, and the bursal lesion score. In ovo 
DNA vaccination with no boost did not provide sufficient 
immunity, and the addition of ChIL-2 or ChIFN-γ did not 
enhance protective immunity. In the ConA-induced lymphocyte 
proliferation assay of peripheral blood lymphocyte collected 
10  days  post-challenge,  there  was  greater  proliferation 
responses in the DNA vaccine plus boost and DNA vaccine 
with ChIL-2 plus boost groups compared to the other groups. 
These findings suggest that priming with DNA vaccine and 
boosting  with  killed  vaccine  is  an  effective  strategy  for 
protecting chickens against vvIBDV.
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Introduction 
  Infectious bursal disease virus (IBDV) causes infectious 
bursal disease (IBD) or Gumboro disease, an acute and highly 
contagious disease that affects chickens at 3 weeks of age 
and older. The disease has a high mortality rate, and chickens 
that survive IBD have a decreased immune response to 
vaccination, are immunosuppressed and vulnerable to a 
variety of secondary infections. This disease is the source 
of enormous economic loss in the poultry industry worldwide 
[23].
  IBDV, a member of the genus Avibirnavirus of the family 
Birnaviridae, is a double-stranded RNA virus with a 
genome consisting of segments A and B [26]. Segment A 
contains two open reading frames encoding VP5 protein 
and a precursor polyprotein that is proteolytically cleaved 
to yield the major structural proteins VP2 and VP3 [14,27]. 
VP2 is thought to be the major host-protective antigen, as 
it can elicit viral-neutralizing antibodies against IBDV [5]. 
Segment B encodes VP1, a protein with RNA-dependent 
RNA polymerase activity [26].
  Vaccination with live attenuated viruses and killed viruses 
has been used to prevent IBD. These live conventional 
vaccines can cause immunosuppression and some bursal 
atrophy, and may not fully protect chickens against the 
very virulent IBDV (vvIBDV) strain and antigenic variants 
of IBDV [34,38]. Several DNA vaccines containing the VP2 
or VP2-VP4-VP3 genes have been tested in chickens in an 
effort to eliminate these side effects [2,3,12,15]. However, 
repeated vaccinations with a large amount of DNA, and 
sometimes the use of an adjuvant, were necessary to 
provide adequate protection against IBDV. It is difficult to 
compare these studies because the methods, vaccination 
schedule, IBDV strains used to develop the vaccine, and 
challenges to the vaccine differed [2,3,12,15,24].
    Recent reports have indicated that a prime-boost 
vaccination strategy could enhance the efficacy of DNA 
vaccines against several pathogens [13,33]. The prime- 132    Jeong Ho Park et al.
Table 1. Protective immunity against very virulent infectious bursal disease virus (vvIBDV) provided by an in ovo prime with DNA 
vaccine followed by a killed-vaccine boost
Presence of  Bursal lesion
Survival
† B/B ratio
§
      Group*   IBDV RNA
‡ score
∥ 
(%) (Mean ± SD)
(%) (mean ± SD)
ELISA antibody titer (mean ± SD)
¶
Pre-challenge Post-challenge
DNA vaccine 
10/10 (100%) 5/10 (50%)
b 2.22 ± 0.63
ab 2.6 ± 0.48 404.8 ± 435.13
abc     11,704 ± 3053.51
a
  plus boost
DNA vaccine with 
 8/10 (80%) 4/8 (50%)
b 1.84 ± 0.50
bc 2.9 ± 0.32 1900 ± 3556.96
a 10,344.71 ± 3207.64
ab
  ChIL-2 plus boost
DNA vaccine with 
 7/10 (70%) 6/7 (85.7%)
a 1.92 ± 0.45
abc 3.0 ± 0.50 486.8 ± 553.12
ab 7,182 ± 2459.17
abc
  ChIFN- γ plus boost
DNA vaccine 
 2/10 (20%) 2/2 (100%)
a 1.15 ± 0.06
c 3.5 ± 0.35 ＜396 (0/10)
d 5,798.5 ± 1887.27
abc
  without boost
Vaccine control  7/10 (70%) 5/7 (71.4%)
a 1.17 ± 0.80
bc 3.2 ± 0.38 2679.75 ± 2488.84
a 11,044 ± 3613.96
a
Challenge control  2/10 (20%) 2/2 (100%)
a 1.66 ± 0.31
bc 3.5 ± 0.35 ＜396 (0/10)
cd  2,724 ± 301.22
bc
Normal control 10/10 (100%) 0/8 (0%)
c 3.59 ± 0.50
a 0.0 ± 0.0 ＜396 (0/10)
bcd ＜396 (0/10)
c
*DNA vaccine plus boost: vaccinated with pcDNA-VP243 vaccine, boost, and challenge; DNA vaccine with IL-2 and boost: vaccinated with
pcDNA-VP243 vaccine mixed with chicken IL-2 (ChIL-2), boost, and challenge; DNA vaccine with IFN-γ and boost: vaccinated with pcDNA-
VP243 vaccine mixed with chicken IFN-γ (ChIFN-γ), boost, and challenge; DNA vaccine without boost: vaccinated with pcDNA-VP243 vaccine
only; Vaccine control: no DNA vaccine, only boost and challenge; Challenge control: no vaccine, only challenge; Normal control: no vaccine
or challenge. 
†Number of surviving chickens at 10 days post-challenge/total number of chickens in each group. 
‡Presence of IBDV RNA in
the bursae of surviving chickens at 10 days post-challenge. Values followed by different lowercase superscripts are significantly different (p
＜ 0.05). 
§The B/B ratio of the surviving chickens 10 days post-challenge. Values followed by different lowercase superscripts are significantly
different (p ＜ 0.05). 
∥Bursal lesion score (mean ± SD). The bursae of surviving chickens were histologically examined at 10 days post-challenge
and scored from 0 to 4 on the basis of increasing severity. 
¶ELISA antibody titers (mean ± SD) measured from blood samples collected 
pre-challenge and at day 10 post-challenge. A titer level greater than 396 was considered to be positive. Values followed by different lowercase
superscripts are significantly different (p ＜ 0.05).
boost vaccination regime typically involved priming with 
a DNA vaccine and boosting with killed vaccines or 
recombinant proteins. This method generated high levels 
of T-cell memory, induced extremely high levels of cell- 
mediated immunity against pathogens [30], and increased 
the antibody response to the vaccine [18]. DNA vaccination 
against IBDV involves priming with DNA vaccine and 
boosting with killed IBDV vaccine or recombinant fowlpox 
expressing the IBDV VP2 gene [8,11]. These prime-boost 
vaccinations protected chickens against challenges by 
standard, variant, or classical IBDV strains [8,11].
  Late-stage chicken embryos are immunologically competent 
and able to respond to antigens [33], and efforts are underway 
to develop a safe and effective in ovo vaccine. In ovo vaccines 
are particularly useful for large-scale poultry industries 
because they reduce labor costs, contamination and deliver 
an accurate dose without affecting hatchability [28].
  Cytokines are vital immune modulators, and their use as 
a genetic adjuvant has been studied for several vaccines 
[1,10,12,37]. For example, chicken interleukin-2 (ChIL-2) 
enhanced the immunogenicity of DNA vaccines against 
IBDV [12], but chicken IFN-γ (ChIFN-γ ) did not [10,32].
    In this study, we evaluated the immunity against the 
vvIBDV strain provided by priming with an in ovo DNA 
vaccine prepared from a vvIBDV strain followed by 
boosting with killed IBV vaccine. We also investigated the 
effectiveness of plasmid-encoded ChIL-2 and ChINF-γ as 
adjuvants. To our knowledge, this is the first reported test 
of an in ovo DNA vaccine with genetic adjuvants followed 
by a killed-vaccine boost to a vvIBDV challenge. 
Materials and Methods
Chickens
  Fertilized eggs of specific-pathogen-free (SPF) White 
Leghorn chickens (Hy-Vac, USA) were incubated. The 
embryos to be vaccinated were inoculated with a plasmid 
formulation on embryonation day 18 (Table 1). Hatched 
layer-type chickens were placed into isolators operated 
under positive air pressure and provided with ad libitum 
food and water during the experimental period. 
Construction and preparation of plasmids 
  The IBDV DNA vaccine containing the plasmid pcDNA- 
VP243, encoding for the VP2, VP3 and VP4 proteins of the 
vvIBDV SH/92 strain, and the plasmid pcDNA-ChIFN-γ, 
encoding for ChIFN-γ, were prepared as previously 
described [15,32].Protection against IBDV with prime-boost vaccination    133
  The ChIL-2 gene was isolated from spleens obtained 
aseptically from 8-week old SPF chickens. The spleens were 
passed through a plastic cell strainer (Becton Dickinson 
Labware, USA), and the lymphocytes were separated 
using Histopaque-1077 (Sigma, USA). The prepared 
splenocytes were rinsed three times in Hanks’ Balanced 
Salt Solution (Invitrogen, USA) and incubated for 6 h at 1 
× 10
7 cells/ml, 40
oC, and 5% CO2 in RPMI-1640 medium 
containing 10% fetal bovine serum (FBS) (Invitrogen, USA) 
supplemented with 12.5 μg/ml concanavalin A (ConA, 
Sigma). Total RNA was isolated and purified from the 
harvested splenocytes using TRIzol reagent (Invitrogen, 
USA) according to the manufacturer's instructions, and 
cDNA was synthesized using random primers (Invitrogen, 
USA). Polymerase chain reaction (PCR) fragments were 
synthesized from the cDNA using the primers IL-2F 
(5'-GCCGCCGCCATGATGTGCAAAGTACTGATCTT
T-3') and IL2-R (5'-TTATTTTTGCAGATATCTC-3'), which 
were synthesized based on the published ChIL-2 sequence 
[36]. The sequence GCCGCCGCC, which is compatible 
with Kozak's rule, was incorporated into the 5' end of the 
IL-2F primer [16]. PCR was performed with 35 cycles of 
denaturation at 95
oC for 1 min, annealing at 55
oC for 1 min, 
and extension at 72
oC for 2 min. The final extension step 
was performed at 72
oC for 10 min. The PCR products were 
analyzed on 1% agarose gels. 
  The PCR products were purified utilizing the GENECLEAN 
Turbo Kit (BIO 101, USA) according to the manufacturer's 
instructions. The purified PCR products were inserted into 
the pcDNA 3.1/V5/His-TOPO vector (Invitrogen, USA) 
and transformed into competent Escherichia coli (TOP 10) 
cells (Invitrogen, USA). Plasmid DNA was prepared using 
a plasmid purification kit (Intron, Korea). The nucleotide 
sequence and orientation of the plasmid construct were 
confirmed by DNA sequencing. The verified plasmid 
construct was named pcDNA-ChIL-2. Large quantities of 
all plasmid DNAs for administration were prepared by 
Aldevron (USA).
In vitro transcription and translation
  In vitro expression of pcDNA-ChIL-2 was performed 
using the TNT Quick Coupled Transcription/Translation 
System (Promega, USA). The protein produced from this 
reaction was electrophoresed on a 12% discontinuous 
SDS- PAGE gel and transferred onto nitrocellulose membranes 
for visualization. The membranes were washed with 
Tris-buffered saline (TBS) and incubated in a blocking 
buffer of TBS containing 0.5% Tween 20. After analysis 
using a translation detection system (Transcend Colorimetric 
Translation Detection System, Promega), streptavidin- 
alkaline phosphatase conjugate was added to the membranes, 
which were then rocked gently for 60 min. Stabilized 
substrate (Western Blue Stabilized Substrate; Promega, 
USA) was then added to visualize the bands.
Immunization and challenge protocol
  SPF eggs were randomly divided into seven experimental 
groups (Table 1). At embryonation day 18, one of four 
preparations for priming in ovo, pcDNA-VP243 (100 μg) 
with pcDNA empty vector (50 μg), pcDNA-VP243 (100 μg) 
with pcDNA-ChIL-2 (50 μg), pcDNA-VP243 (100 μg) 
with pcDNA-ChINF-γ (50 μg), or sterile PBS (pH 7.4), 
was administered directly into the amniotic sac using a 1 
inch 23-gauge needle. The hatching rates for the experimental 
groups were 95∼100%. At 1 week of age, the chickens, 
with the exception of the DNA vaccine with no boost, 
challenge, and normal control groups, were boosted 
intramuscularly with commercial killed IBD vaccine 
containing IBDV (Gumboro D78) emulsified in an oil base 
(Intervet, Netherlands).
  At 3 weeks of age, all of the chickens, except those in the 
normal control group, were orally challenged with 1 × 10
3.8 
50% egg lethal dose (ELD50) of the vvIBDV SH/92 strain 
and observed for 10 days. At day 10 post-challenge, all 
surviving chickens were bled and euthanized for necropsy. 
The bursa and body weights were determined and the bursa 
weight/body weight (B/B) ratios calculated [B/B × 1,000]. 
The bursae of Fabricius were examined for histopathological 
lesions, and RT-PCR was used to detect evidence of IBDV 
RNA.
Detection of IBDV RNA in the bursa of Fabricius
  IBDV RNA was extracted from bursae and purified using 
the Viral Gene-spin kit (Intron, Korea) according to the 
manufacturer’s instructions. A 474-bp hypervariable region 
in the VP2 gene was amplified by RT-PCR with the primers 
P2.3 (5'-CCCAGAGTCTACACCATA-3') and RP5.3 (5'- 
TCCTGTTGCCACTCTTTC-3') [20]. The RT-PCR 
conditions were as follows: 42°C for 60 min followed by 
heating at 94
oC for 5 min; 35 cycles of 94
oC for 30 sec, 
51°C for 30 sec, and 72°C for 2 min; and 74°C for 15 min. 
The PCR products were analyzed on 1.5% agarose gels.
Histopathology of the bursa of Fabricius
  Bursae collected from the surviving chickens at day 10 
post-challenge were fixed in 10% buffered formalin. After 
routine processing, the tissues were embedded in paraffin, 
cut into approximately 3-μm sections, and prepared for 
hematoxylin and eosin (H&E) staining for histological 
examination. The bursal lesions were graded in five 
categories (0∼4): 0, no lesions; 1, mild scattered cell 
depletion in a few follicles; 2, moderate with 1/3-1/2 of the 
follicles atrophied or with depleted cells; 3, diffuse with 
atrophy in all follicles; and 4, acute inflammation and acute 
necrosis typical of IBD [6]. The H&E stained tissues were 
examined by two veterinary pathologists who were blind to 
the treatment groups. When there was a discrepancy in the 
grading, the pathologists reached an agreement after 134    Jeong Ho Park et al.
Fig. 1. Colorimetric translation detection of an SDS-PAGE 
analysis of a coupled in vitro transcription/translation reaction. 
Lane M = SDS-PAGE molecular weight standard, broad range 
(Invitrogen); Lane 1 = pcDNA-chicken IL-2 (ChIL-2). The 
position of the chicken interleukin 2 protein is on the right side. 
The sizes of the marker proteins are on the left.
discussion.
Lymphocyte proliferation assay
  Lymphocyte proliferation assays were performed as 
described [15]. Briefly, peripheral blood was collected 
aseptically from chickens before the challenge and at 10 
days post-challenge. The blood collected from chickens of 
each group was pooled and then peripheral blood lymphocytes 
from pooled blood of each group were prepared. Lymphocytes 
were separated using Histopaque-1077 (Sigma, USA), 
washed three times, and resuspended in RPMI-1640 
medium supplemented with 10% FBS. The cells were 
placed in 96-well flat-bottom tissue culture plates at 1.25 × 
10
6 cells/well. ConA (12.5 μg/ml) was added to each well 
except for the negative-control well. The plates were 
incubated at 40
oC for 48 h in 5% CO2. Lymphocyte proliferation 
activity was measured using WST-8 working solution 
(Dojindo Laboratories, Japan). The optical density (OD) 
was determined at 450 nm, and the stimulation index (SI) 
was calculated as follows: SI = mean OD of ConA- 
stimulated cells / mean OD of unstimulated cells. 
Enzyme-linked  immunosorbent  assay  (ELISA)  of 
antibodies
  Blood samples were collected from the birds in each 
experimental group before the challenge and at 10 days 
post-challenge. Serum antibody titers were determined for 
the experimental groups using an Infectious Bursal 
Disease Antibody Test Kit (IDEXX, USA) as described 
[15]. Titers greater than 396 were considered positive.
Statistical analysis
  All analyses were performed using SAS 9.0 statistical 
software (SAS Institute, USA). The non-parametric Kruskal- 
Wallis rank test with pairwise multiple comparison, using 
the Dunn method for post-hoc analysis, was used to 
evaluate the differences in the B/B ratios among the 
groups. A one-way ANOVA was used to assess individual 
differences in serum antibody titers and lymphocyte 
proliferation assays. Levene's test for homogeneity of the 
data was used to determine the equality of variances among 
groups [9]. p values below 0.05 were considered significant.
Results
Construction  of  plasmid  and  characterization  in 
vitro
  A 441-bp fragment of the ChIL-2 gene, including Kozak’s 
sequence, was amplified by RT-PCR (data not shown). The 
ChIL-2 RT-PCR product was purified and inserted into the 
pcDNA3.1/V5/His-TOPO vector. The protein expressed 
from pcDNA-ChIL-2 was confirmed by in vitro transcription/ 
translation and detection (Fig. 1). A band with a molecular 
weight of approximately 18.4 kDa was observed [35].
Immunization and challenge with vvIBDV 
  The effectiveness of a prime-boost vaccination strategy in 
enhancing the immunogenicity and protective effect of a 
DNA vaccine against IBDV was investigated. The experimental 
groups were immunized with DNA vaccine alone or 
vaccine mixed with selected genetic adjuvants at day 18 of 
embryonation, and boosted with killed vaccine at 1 week of 
age. The chickens were challenged with vvIBDV at 3 
weeks of age. After 10 days of observation, the mortality 
rate, presence of IBDV RNA, B/B ratios, serum antibody 
titers, and ConA-induced peripheral blood lymphocyte 
proliferation were recorded (Table 1, Figs. 2 and 3).
    Eggs given the vaccine and control eggs both had a 
hatchability rate of above 95%, indicating that the DNA 
vaccine did not affect embryo hatchability. The clinical 
signs of IBD (anorexia, depression, and ruffled feathers) 
began to appear at three days after the challenge, and these 
chickens died at 2∼3 days after the first clinical signs. The 
DNA vaccine and boost group had a 100% survival rate, 
higher than those of the other groups. The DNA vaccine 
with ChIL-2 plus boost group also had a much lower 
mortality rate than the other groups. The DNA vaccine 
without boost group had a 20% survival rate, which was 
identical to that of the challenge control group.
  IBDV RNA was detected in the bursa of Fabricius in 
every group except the normal control group, but it was 
present at significantly lower levels in the DNA vaccine 
with boost and DNA vaccine with ChIL-2 plus boost 
groups in comparison to the other groups (p ＜ 0.05).
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Fig. 3. The mitogenic responses of peripheral blood lymphocytes
prepared from chickens before and after being challenged with 
the very virulent IBDV SH/92 strain. Cells were stimulated with
Con A (1.25 μg/well) and each value was presented as the mean
of the ELISA optical density obtained from randomly selected 
chickens ± SD. Within same day, values followed by different 
lowercase superscripts are significantly different (p < 0.05). 
Stimulation index (SI) = (mean OD of ConA-stimulated cells) / 
(mean OD of unstimulated cells). 
Fig. 2. The size (A) and hematoxylin-eosin-stained sections (B) 
of the representative bursa of Fabricius recovered from chickens 
either with or without DNA vaccine and adjuvants at day 10 
post-challenge with very virulent IBDV SH/92 strain. Groups 
are: 1. DNA vaccine plus boost; 2. DNA vaccine with chicken 
IL-2 plus boost; 3. DNA vaccine with chicken IFN-γ plus boost;
4. DNA vaccine without boost; 5. Vaccine control; 6. Challenge 
control; 7. Normal control. Scale bars = 50 μm. 
vvIBDV challenge was determined using the B/B ratio and 
a histological analysis of lesions in the bursa of Fabricius 
collected from the surviving chickens at 10 days post- 
challenge. The B/B ratios in the DNA vaccine with boost 
and DNA vaccine with ChIFN-γ plus boost groups were 
higher than in the other groups, and not significantly lower 
than that of the normal control group. Bursal atrophy was 
noted in all of the chickens that survived vvIBDV infection. 
The bursal lesions were characterized by lymphoid depletion 
and edema in the follicles, fibroplasias in the interfollicular 
connective tissues, and proliferation of the reticular epithelial 
cells. The DNA vaccine plus boost group had a lower bursal 
lesion score than the other groups; in particular the DNA 
vaccine without boost, vaccine control, and challenge control 
groups. The DNA vaccine with ChIL-2 plus boost and DNA 
vaccine with ChIFN-γ plus boost groups had similar bursal 
lesion scores, which were higher than those of the DNA 
vaccine plus boost group. Bursal atrophy and lesions were 
also noted in the DNA vaccine with boost group, but most 
of the lymphatic nodules were still present and had a 
considerable number of differentiated lymphocytes. In 
contrast, in the challenge control group, several lymphatic 
nodules were lost and replaced by the stroma of reticular 
epithelial cells. No protective effect was observed in the 
DNA vaccine without boost group.
  Antibodies to IBDV were detectable in all groups before 
the challenge, with the exception of the DNA vaccine 
without boost, challenge control, and normal control groups. 
The DNA vaccine with ChIL-2 plus boost and the vaccine 
control groups had the highest antibody titers. Ten days 
after the challenge, all surviving chickens, except those in 
the normal control group, had detectable IBDV antibody 
levels. ELISA antibody titers in the DNA vaccine plus 
boost and vaccine control groups were significantly higher 
than those in the challenge control group (p  <　0.05, Table 1).
  The kinetic changes in ConA-induced peripheral blood 
lymphocyte proliferation in each group of chickens were 
measured using the WST-8 assay before and after the 
vvIBDV SH/92 strain challenge (Fig. 3). Immediately 136    Jeong Ho Park et al.
prior to the challenge, the peripheral blood lymphocyte 
activity was significantly higher in the DNA vaccine with 
ChIFN-γ plus boost group than in the vaccine control group 
(p ＜ 0.05). The peripheral blood lymphocyte activity in 
the DNA vaccine plus boost and DNA vaccine with 
ChIL-2 plus boost groups was significantly higher than in 
the DNA vaccine without boost group 10 days post- 
challenge (p ＜ 0.05).
Discussion
  Recently, several adjuvants and the prime-boost vaccination 
strategy have been used to improve the protective immunity 
of IBDV DNA vaccines [8,11,32]. This study investigated 
whether priming with an in ovo DNA vaccine with genetic 
cytokines followed by heterologous boosting with killed 
vaccine offered protection against vvIBDV. Because the 
vvIBDV strain produces a high rate of mortality in 
chickens, it is important to develop an effective vaccine 
against this virus [39]. Lymphoid necrosis and depletion 
are still observed in chickens protected by vaccination with 
attenuated live IBDV vaccine strains [38]. 
  The DNA vaccine plus boost strategy was more effective 
than the other treatments as measured by the B/B ratio, the 
bursal lesion score, and the presence of IBDV RNA in the 
bursae, as well as the survival rate. We found that 100% of 
the chickens in the in ovo DNA vaccine plus boost group 
and 80% of the chickens in the in ovo DNA vaccine with 
ChIL-2 plus boost group survived after the challenge with 
vvIBDV. In a previous study using an identical DNA 
vaccine (pcDNA-VP243), 2-week-old chickens were 
injected twice at 2-week intervals with 200 μg of the 
vaccine, then challenged with vvIBDV 2 weeks after the 
second immunization. Their survival rate was 70% [15], 
showing that priming with an in ovo DNA vaccine and 
boosting with killed vaccine provides better protection 
than post-hatch DNA vaccination. There was considerably 
less bursal atrophy and lower bursal lesion score in the in 
ovo DNA vaccine plus boost and in ovo DNA vaccine with 
ChIL-2 plus boost groups, indicating that these strategies 
provided more effective protection from the virus, viral 
spreading, and cellular destruction than the others. 
    Several studies have investigated the efficacy of the 
heterologous prime-boost strategy to produce humoral and 
cell-mediated immunity against several pathogens. Priming 
with a DNA vaccine followed by a killed or live-vaccine or 
recombinant-protein boost have been tested against IBDV, 
infectious bronchitis virus, and influenza virus [8,11,13, 
18]. Chickens primed with IBDV DNA vaccine and boosted 
with recombinant fowlpox expressing the VP2 gene were 
protected against vvIBDV, but chickens that received the 
DNA vaccine or recombinant fowlpox alone were not 
protected, as indicated by bursal damage and B/B ratios 
[8]. Post-hatch priming with IBDV DNA vaccine and 
boosting with killed vaccine have been reported to protect 
chickens against homologous or heterologous IBDV [11]. 
In that experiment, as there were no mortalities in the 
experimental groups, vaccine efficacy was measured by 
gross bursal lesions and the B/B ratios.
  The DNA priming vaccine can be administered either in 
ovo or in hatched chickens [8,11,13]. In ovo vaccinations 
are usually performed at embryonation day 18 and have 
been investigated as an alternative to post-hatch vaccination 
for several avian pathogens [8,13]. In this method, the 
appropriate expression of genes inserted into the plasmid 
vector is essential for the production of protective immunity 
in the embryos. Chicken embryos in the late stage have an 
immunological response to antigens, and in ovo immunization 
would produce immunity earlier than post-hatch inoculation 
and allow rapid and massive vaccination using the 
automatic egg injection system [4]. In ovo vaccination of 
chickens with an intermediate strain of IBDV produced 
active immunity and quick recovery from bursal damage 
and provided protection similar to that of post-hatching 
vaccination [4]. The S1 protein, including the IBV S1 gene, 
was expressed in the bursa and heart of chicken embryos 
following the delivery of DNA vaccine into the allantoic 
sac, with the expression of the IBV and NDV viral proteins 
detected in the liver and muscle of embryos that received 
plasmid vector containing the viral gene [13]. In our 
experiment, the chickens that received in ovo DNA 
vaccine with no boost had low protective immunity, 
although the priming effect of the in ovo DNA vaccine was 
confirmed in the DNA vaccine plus boost group. Our 
results were consistent with those of another study using in 
ovo vaccination with a recombinant plasmid containing the 
VP2 gene of IBDV, in which vaccination without boosting 
failed to provide complete protection against the viral 
challenge [8]. The incomplete protection may be explained 
by DNase activity detected in the amniotic fluid. [13] DNA 
vaccine is generally delivered into the amniotic fluid, and 
it is possible that the DNase degraded the plasmid DNA. 
Cationic liposomes or neutral lipids could be used to 
overcome degradation of the DNA vaccine by DNase [29].
  Both humoral immunity and cell-mediated immunity are 
involved in the protection against IBDV in chickens [31]. 
The commercial IBDV antibody kit used in this experiment 
was designed to evaluate the status of immunity to IBDV, 
and only serum samples with antibody titers greater than 
396 were considered positive. Before the challenge, all 
groups that received the booster, including the vaccine 
control group that received killed vaccine alone, exhibited 
antibody titers greater than 396, indicating that the booster 
produced humoral immunity against IBDV. Surviving 
chickens of the boosted groups, including the vaccine 
control, had higher antibody titers after the challenge than 
the challenge control group, suggesting that the prime- 
boost strategy was effective. Chickens that received the Protection against IBDV with prime-boost vaccination    137
DNA vaccination followed by boosting with killed vaccine 
after hatching had higher antibody titers than chickens 
boosted with homologous DNA vaccine [11]. Cell-mediated 
immunity involving T cells appears to contribute to the 
protection against IBDV [15,34,40]. In a previous study, 
we showed that lymphocytes collected from chickens 
immunized against IBDV by DNA vaccination continued 
to proliferate when stimulated with ConA [15]. Chickens 
with severely compromised antibody-producing ability 
following treatment with cyclophosphamide retained 
memory T cells and the immune response that destroys 
IBDV in the absence of antibodies [40]. However, 
compromising functional T cells by neonatal thymectomy 
and Cyclosporin A resulted in a lack of protection against 
IBDV following immunization with an inactivated IBDV 
vaccine [34]. Further, priming with in ovo DNA vaccine 
and boosting with recombinant fowlpox has been reported 
to produce immunity in chickens, with no antibody detected 
before or after the viral challenge [8]. In our study, the SI 
was higher after the challenge in the DNA vaccine plus 
boost and the DNA vaccine with ChIL-2 plus boost groups 
compared to the other groups. This finding indicates that 
peripheral blood lymphocyte activity was maintained after 
the challenge, and that the cell-mediated immune response 
involving T cells contributed to the immunity. Therefore, it 
was likely that the high level of protection in the DNA 
vaccine plus boost group was the result of both humoral 
and cell-mediated immunity.
    Cytokines can be used to enhance the efficacy of 
conventional or genetic vaccines that do not produce a 
sufficient immune response when used alone. Interleukin 2 
and INF-γ are the primary adjuvants investigated for use in 
poultry vaccines and several studies have investigated the 
efficacy of INF-γ as an adjuvant against pathogens [10,22, 
32]. Duck INF-γ used as an adjuvant increased the 
protective efficacy of a DNA vaccine against duck hepatitis 
B virus [22]. However, ChINF-γ co-administered with 
IBDV DNA vaccine in hatched chickens did not enhance 
protective immunity against IBDV [10,32]. The present 
study showed that co-delivery of ChIL-2 or ChINF-γ with 
IBDV DNA vaccine did not enhance immunity to vvIBDV, 
and that the adjuvants partially decreased the protective 
efficacy compared with DNA vaccine plus boost alone. 
Our results for ChINF-γ in an in ovo vaccination trial were 
similar to those of previous studies performed in hatched 
chickens [10,32], with the promoter-driven expression of 
SV40 and CMV in myoblasts significantly reduced by the 
addition of INF-γ [7]. Therefore, ChINF-γ expressed by 
pcDNA-ChINF-γ co-delivered with the DNA vaccine may 
inhibit the expression of viral genes under the control of the 
CMV promoter. It appeared that the effects of INF-γ on the 
immune response are likely to be dependent on the animal 
species, the types of combined antigens, and the promoter 
of the plasmid expressing the cloned gene [7,10,22,32].
    The immune-enhancing function of ChIL-2 was not 
observed in this in ovo IBDV DNA vaccination scheme, 
although others have observed that ChIL-2 increased the 
protective immune response of IBDV DNA vaccine or live 
IBDV vaccine in chickens, and immunization with 
bicistronic DNA vaccine expressing IBDV-VP2 and ChIL-2 
to 2-week-old chickens showed effective protection against 
IBDV [12,17,37]. In ovo immunization with ChIL-2 plus a 
plasmid encoding 3-1E Eimeria gene enhanced protective 
intestinal immunity against coccidiosis in chickens, but 
subcutaneous injection did not increase host immunity 
[21,25]. Therefore, the effects of IL-2 on the immune 
response appear to be affected by the types and combined 
methods of vaccines and adjuvants, the route and time of 
inoculation, the promoter of the plasmid expressing the 
cloned genes, and animal species.
  In summary, we have demonstrated that in ovo DNA 
vaccination followed by a killed vaccine boost completely 
protected chickens against mortality after challenge with 
vvIBDV. Further studies may be needed to improve the 
efficacy of DNA vaccines by varying parameters such as 
the interval between priming and boosting, the vaccine 
used for boosting, and the use of new chemical or genetic 
adjuvants. We are currently examining these factors to 
improve the protective immune response to vaccination in 
chickens.
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